Evidence map›Paper›PMID 26061331›Full record

SynthesisMedicine2015

Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review.

Ole Haagen Nielsen, Mark Ainsworth, Mehmet Coskun, Günter Weiss

Registry-linked trialOpen access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02760940 (Anemia Treatment in Inflammatory Bowel Disease), which is not on this map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02760940 phase4unknown statusnot on this mapstarted 2016, after this paper: background citation

Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment

TypeinterventionalSponsorFederal University of Juiz de ForaRan2016 to 2018Enrolled200ConditionsAnemia, Bowel Diseases, InflammatoryArmsoral liposomal iron
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Effectiveness and safety of intravenous iron in ulcerative colitis: A real-world study of impact of disease activity and iron preparations.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ole Haagen NielsenFrom the Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark (OHN, MA, MC); and Department of Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria (GW).
Mark Ainsworth
Mehmet Coskun
Günter Weiss
Innsbruck Medical University · AT

Funding

Austrian Science Fund FWF TRP 188
6 · The paper itself

Abstract

Anemia is the most frequent complication of inflammatory bowel disease (IBD), but anemia, mostly due to iron deficiency, has long been neglected in these patients. The aim was to briefly present the pathophysiology, followed by a balanced overview of the different forms of iron replacement available, and subsequently, to perform a systematic review of studies performed in the last decade on the treatment of iron-deficiency anemia in IBD. Given that intravenous therapies have been introduced in the last decade, a systematic review performed in PubMed, EMBASE, the Cochrane Library, and the websites of WHO, FDA, and EMA covered prospective trials investigating the management of iron-deficiency anemia in IBD published since 2004. A total of 632 articles were reviewed, and 13 articles (2906 patients) with unique content were included. In general, oral supplementation in iron-deficiency anemia should be administered with a target to restore/replenish the iron stores and the hemoglobin level in a suitable way. However, in patients with IBD flares and inadequate responses to or side effects with oral preparations, intravenous iron supplementation is the therapy of choice. Neither oral nor intravenous therapy seems to exacerbate the clinical course of IBD, and intravenous iron therapy can be administered even in active disease stages and concomitantly with biologics. In conclusion, because many physicians are in doubt as to how to manage anemia and iron deficiency in IBD, there is a clear need for the implementation of evidence-based recommendations on this matter. Based on the data presented, oral iron therapy should be preferred for patients with quiescent disease stages and trivial iron deficiency anemia unless such patients are intolerant or have an inadequate response, whereas intravenous iron supplementation may be of advantage in patients with aggravated anemia or flares of IBD because inflammation hampers intestinal absorption of iron.

Indexed as

Anemia, Iron-DeficiencyHumansInflammatory Bowel DiseasesIronIron

Identifiers

PMID26061331
PMCPMC4616486
OpenAlexW2312310467

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.